A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate Meeting Abstract
| Authors: | Hansen, A. R.; Shapiro, G.; Do, K. T.; Kumar, R.; Martin-Liberal, J.; Higano, C. S.; Wisinski, K. B.; Dean, E. J.; Heath, E. I.; Rathkopf, D. E.; Linch, M. D.; Barry, S. T.; Brugger, W.; De Bruin, E.; Colebrook, S.; Klinowska, T.; Mitchell, P. D.; Moorthy, G.; De Bono, J. S.; Siu, L. L. |
| Abstract Title: | A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Start Page: | 124s |
| Language: | English |
| ACCESSION: | WOS:000411895704173 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.2570 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 2570 -- Source: Wos |
